Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 102

Sort by

Sort Order Select

Journal Articles

Enhanced Antitumoral Efficacy of ARI0002h CAR-T with CD28-TMD in Normal and Low BCMA Expressing Myeloma Cells

Luis Gerardo Rodríguez-Lobato, Oriol Cardus, Joan Mañé Pujol, Anthony Battram, David F. Moreno, Lorena Perez-Amill, Beatriz Martín-Antonio, Aina Oliver-Caldés, Anna De Daniel, Natalia Tovar, M Teresa Cibeira López, Laura Rosinol Dachs, Manel Juan, Alvaro Urbano-Ispizua, Carlos Fernández de Larrea

Blood (2024) 144 (Supplement 1): 359.

https://doi.org/10.1182/blood-2024-200123

Published: 2024

Journal Articles

M-Easix (Better Than EASIX) Correlates with Specific Endotheliopathy Biomarkers, Predicts Severe CAR-T Cell Toxicities and Discriminates from Sepsis

Blood (2024) 144 (Supplement 1): 3423.

https://doi.org/10.1182/blood-2024-208083

Published: 2024

Journal Articles

CART Cell Therapy Targeting CD84 Alone or in Combination with CD19 for the Treatment of B-Cell Malignancies

Ane Altuna Mongelos, Lorena Perez Amill, Maria Val-Casals, Sergio Peña, Mercedes Armand-Ugon, Jose Ramón Álamo Moreno, Juan Gonzalo Correa, Alvaro Urbano-Ispizua, Julio Delgado, Claudio Santos, Manel Juan, Nela Klein-Gonzalez

Blood (2024) 144 (Supplement 1): 1034.

https://doi.org/10.1182/blood-2024-207309

Published: 2024

Journal Articles

Outpatient Reinfusion of CAR-T Cesnicabtagene Autoleucel (ARI0002h) in Multiple Myeloma Is Feasible and Safe

Beatriz Merchán Muñoz, Alexandra Martínez-Roca, Nuria Ballestar, Cristina Gallego, Nuria Martínez-Cibrián, Valentin Ortiz-Maldonado, Luis Gerardo Rodriguez-Lobato, Nil Albiol, Pilar Ayora, Carla Ramos, Maria Sanchez-Castañon, Manel Juan, Julio Delgado, Jordi Esteve Reyner, Alvaro Urbano-Ispizua, Carlos Fernández de Larrea, Francesc Fernández-Avilés

Blood (2024) 144 (Supplement 1): 7619.

https://doi.org/10.1182/blood-2024-211330

Published: 2024

Journal Articles

The CAR-Hematotox Identifies Patients at High Risk of Infectious/Inflammatory Complications in a Cohort of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Treated with ARI-0001 (Varnimcabtagene Autoleucel)

Blood (2024) 144 (Supplement 1): 2084.

https://doi.org/10.1182/blood-2024-206082

Published: 2024

Journal Articles

Sequential Scmultiomics of In Vivo CAR-T Cells Allows Characterization of Transcriptional Differences between Patients, and Identifies IL10 As a Potential Mechanism of Resistance to CAR-T Cells in MM

Blood (2023) 142 (Supplement 1): 3433.

https://doi.org/10.1182/blood-2023-182887

Published: 2023

Journal Articles

Validation of ELN 2022 Risk Classification in Patients Diagnosed with AML Undergoing Allogeneic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 4230.

https://doi.org/10.1182/blood-2023-185484

Published: 2023

Journal Articles

ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1026.

https://doi.org/10.1182/blood-2023-180828

Published: 2023

Journal Articles

Impact of Salvage and Bridging Therapy in Adult Patients with Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) Referred for Anti-CD19 CAR T-Cell Therapy: An Intention to Treat Analysis

Blood (2023) 142 (Supplement 1): 4875.

https://doi.org/10.1182/blood-2023-187226

Published: 2023

Journal Articles

Evaluation of the Use of Post-Transplant Cyclophosphamide in Patients Diagnosed of Myelodysplastic Syndrome Who Undergo Allogenic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 7018.

https://doi.org/10.1182/blood-2023-181076

Published: 2023

Journal Articles

Longitudinal Transcriptomic Analysis of CAR-T Cells at Single-Cell Level Allows the Identification of Molecular Mechanisms Promoting Long-Term CAR-T Cell Persistence in MM

Blood (2023) 142 (Supplement 1): 2069.

https://doi.org/10.1182/blood-2023-182933

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplantation with Sequential-Based Conditioning in Refractory / Relapsed Acute Myeloid Leukemia: Experience from a Single Institution

Blood (2023) 142 (Supplement 1): 3550.

https://doi.org/10.1182/blood-2023-179852

Published: 2023

Journal Articles

Varnimcabtagene Autoleucel (ARI-0001) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)

Blood (2023) 142 (Supplement 1): 3483.

https://doi.org/10.1182/blood-2023-182896

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide-Based Prophylaxis and Its Impact on the Immune Reconstitution and the Incidence of Infectious Complications

Blood (2023) 142 (Supplement 1): 2200.

https://doi.org/10.1182/blood-2023-186687

Published: 2023

Journal Articles

CD84: A Novel Target for CAR T-Cell Therapy for Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 7379–7381.

https://doi.org/10.1182/blood-2022-165339

Published: 2022

Journal Articles

BCMA CAR-T Cell Phenotype and Functionality Is Affected By Disease Stage of Multiple Myeloma Patients

Blood (2022) 140 (Supplement 1): 12708–12710.

https://doi.org/10.1182/blood-2022-163149

Published: 2022

Journal Articles

Endotheliopathy, Innate-Immune Activation and Hemostatic Misbalance Underlying CAR-T Cell Toxicities: Tools for Early and Differential Diagnosis

Ana Belén Moreno-Castaño, Sara Fernandez, Marta Palomo, Julia Martinez-Sanchez, Alex Ramos, Patricia Molina, Marc Pino, Valentín Ortiz-Maldonado, Julio Delgado, Carlos Fernández De Larrea, Álvaro Urbano-Ispizua, Gines Escolar, Enric Carreras, Francesc Fernández-Avilés, Pedro Castro, Maribel Diaz-Ricart

Blood (2022) 140 (Supplement 1): 7427–7428.

https://doi.org/10.1182/blood-2022-169293

Published: 2022

Journal Articles

Genetic Disruption of Blimp-1 Drastically Augments the Persistence and Anti-Tumour Efficacy of BCMA-Targeting CAR-T Cells

Anthony M Battram, Aina Oliver-Caldes, Miquel Bosch i Crespo, Oriol Cardus, David F. Moreno, Luis Gerardo Rodríguez-Lobato, Alvaro Urbano-Ispizua, Carlos Fernandez de Larrea

Blood (2022) 140 (Supplement 1): 2360–2361.

https://doi.org/10.1182/blood-2022-162399

Published: 2022

Journal Articles

Co-Transduced CD19/BCMA Dual-Targeting CAR-T Cells for the Treatment of Non-Hodgkin Lymphoma

Mireia Bachiller, Cèlia Dobaño-López, Alba Rodríguez-García, Joan Castellsagué, Marta Gimenez-Alejandre, Asier Antoñana-Vildosola, Beatriz Martin-Antonio, Julio Delgado, Patricia Pérez-Galán, Manel Juan, Álvaro Urbano-Ispizua, Sonia Guedan

Blood (2022) 140 (Supplement 1): 7386–7387.

https://doi.org/10.1182/blood-2022-168651

Published: 2022

Journal Articles

Trial in Progress: A Randomized Phase II Study of MB-CART2019.1 Compared to Standard of Care Therapy in Patients with Relapsed/Refractory DLBCL Ineligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation - DALY 2-EU Trial

Peter Borchmann, Peter Vandenberghe, Alvaro Urbano-Ispizua, Corinne Haioun, Francois Lemonnier, Laimonas Griskevicius, Sébastien Maury, Silke Holtkamp, Birte Friedrichs, Gregor Zadoyan, Linda Hanssens, Toon Overstijns, Mario Assenmacher, Ulf Bethke, Iris Bürger, Olaf Reer, Ulrich Jaeger, Marie José Kersten

Blood (2022) 140 (Supplement 1): 12784–12785.

https://doi.org/10.1182/blood-2022-164650

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Enhanced Antitumoral Efficacy of ARI0002h CAR-T with CD28-TMD in Normal and Low BCMA Expressing Myeloma Cells

M-Easix (Better Than EASIX) Correlates with Specific Endotheliopathy Biomarkers, Predicts Severe CAR-T Cell Toxicities and Discriminates from Sepsis

CART Cell Therapy Targeting CD84 Alone or in Combination with CD19 for the Treatment of B-Cell Malignancies

Outpatient Reinfusion of CAR-T Cesnicabtagene Autoleucel (ARI0002h) in Multiple Myeloma Is Feasible and Safe

The CAR-Hematotox Identifies Patients at High Risk of Infectious/Inflammatory Complications in a Cohort of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Treated with ARI-0001 (Varnimcabtagene Autoleucel)

Sequential Scmultiomics of In Vivo CAR-T Cells Allows Characterization of Transcriptional Differences between Patients, and Identifies IL10 As a Potential Mechanism of Resistance to CAR-T Cells in MM

Validation of ELN 2022 Risk Classification in Patients Diagnosed with AML Undergoing Allogeneic Hematopoietic Cell Transplantation

ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma

Impact of Salvage and Bridging Therapy in Adult Patients with Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) Referred for Anti-CD19 CAR T-Cell Therapy: An Intention to Treat Analysis

Evaluation of the Use of Post-Transplant Cyclophosphamide in Patients Diagnosed of Myelodysplastic Syndrome Who Undergo Allogenic Hematopoietic Cell Transplantation

Longitudinal Transcriptomic Analysis of CAR-T Cells at Single-Cell Level Allows the Identification of Molecular Mechanisms Promoting Long-Term CAR-T Cell Persistence in MM

Allogeneic Hematopoietic Cell Transplantation with Sequential-Based Conditioning in Refractory / Relapsed Acute Myeloid Leukemia: Experience from a Single Institution

Varnimcabtagene Autoleucel (ARI-0001) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)

Post-Transplant Cyclophosphamide-Based Prophylaxis and Its Impact on the Immune Reconstitution and the Incidence of Infectious Complications

CD84: A Novel Target for CAR T-Cell Therapy for Acute Myeloid Leukemia

BCMA CAR-T Cell Phenotype and Functionality Is Affected By Disease Stage of Multiple Myeloma Patients

Endotheliopathy, Innate-Immune Activation and Hemostatic Misbalance Underlying CAR-T Cell Toxicities: Tools for Early and Differential Diagnosis

Genetic Disruption of Blimp-1 Drastically Augments the Persistence and Anti-Tumour Efficacy of BCMA-Targeting CAR-T Cells

Co-Transduced CD19/BCMA Dual-Targeting CAR-T Cells for the Treatment of Non-Hodgkin Lymphoma

Trial in Progress: A Randomized Phase II Study of MB-CART2019.1 Compared to Standard of Care Therapy in Patients with Relapsed/Refractory DLBCL Ineligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation - DALY 2-EU Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only